Teplizumab induces human gut-tropic regulatory cells in humanized mice and patients

Science Translational Medicine

Volumn 4, Issue 118, 2012, Pages

  Waldron Lynch, Frank ^a   Henegariu, Octavian ^a   Deng, Songyan ^a   Preston Hurlburt, Paula ^a   Tooley, James ^a   Flavell, Richard ^a   Herold, Kevan C ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA4 INTEGRIN; CHEMOKINE RECEPTOR CCR6; INTERLEUKIN 10; NATALIZUMAB; TEPLIZUMAB; TRANSCRIPTION FACTOR FOXP3; ANTIDIABETIC AGENT; CD3 ANTIGEN; FORKHEAD TRANSCRIPTION FACTOR; FOXP3 PROTEIN, HUMAN; L SELECTIN; MONOCLONAL ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN BINDING; ARTICLE; CD4+ CD25+ T LYMPHOCYTE; CELL ADHESION; CELL MIGRATION; CELL POPULATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOSE RESPONSE; DRUG MECHANISM; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; IMMUNOMODULATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; PROTEIN SYNTHESIS INHIBITION; REGULATORY T LYMPHOCYTE; SINGLE DRUG DOSE; T LYMPHOCYTE ACTIVATION; ANIMAL; CELL MOTION; CYTOLOGY; DNA MICROARRAY; DRUG EFFECT; GASTROINTESTINAL TRACT; IMMUNOLOGY; INSULIN DEPENDENT DIABETES MELLITUS; METABOLISM; MOUSE; MUCOSA; SMALL INTESTINE;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIGENS, CD3; CELL MOVEMENT; DIABETES MELLITUS, TYPE 1; FORKHEAD TRANSCRIPTION FACTORS; GASTROINTESTINAL TRACT; HUMANS; HYPOGLYCEMIC AGENTS; INTERLEUKIN-10; INTESTINE, SMALL; L-SELECTIN; MICE; MUCOUS MEMBRANE; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; RECEPTORS, CCR6; T-LYMPHOCYTES, REGULATORY;

EID: 84856274206     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3003401     Document Type: Article

References (38)

1. M. Feldmann, R. N. Maini, Anti-TNF therapy, from rationale to standard of care: What lessons has it taught us? J. Immunol. 185, 791-794 (2010).
2. J. M. Kremer, H. K. Genant, L. W. Moreland, A. S. Russell, P. Emery, C. Abud-Mendoza, J. Szechinski, T. Li, Z. Ge, J. C. Becker, R. Westhovens, Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: A randomized trial. Ann. Intern. Med. 144, 865-876 (2006).
3. C. H. Polman, P. W. O'Connor, E. Havrdova, M. Hutchinson, L. Kappos, D. H. Miller, J. T. Phillips, F. D. Lublin, G. Giovannoni, A. Wajgt, M. Toal, F. Lynn, M. A. Panzara, A. W. Sandrock; AFFIRM Investigators, A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N. Engl. J. Med. 354, 899-910 (2006).
4. J. Keane, S. Gershon, R. P.Wise, E. Mirabile-Levens, J. Kasznica, W. D. Schwieterman, J. N. Siegel, M. M. Braun, Tuberculosis associated with infliximab, a tumor necrosis factor α-neutralizing agent. N. Engl. J. Med. 345, 1098-1104 (2001).
5. B. O. Roep, M. Peakman, Surrogate end points in the design of immunotherapy trials: Emerging lessons from type 1 diabetes. Nat. Rev. Immunol. 10, 145-152 (2010).
6. G. Suntharalingam, M. R. Perry, S. Ward, S. J. Brett, A. Castello-Cortes, M. D. Brunner, N. Panoskaltsis, Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N. Engl. J. Med. 355, 1018-1028 (2006).
7. F. Waldron-Lynch, K. C. Herold, Immunomodulatory therapy to preserve pancreatic β-cell function in type 1 diabetes. Nat. Rev. Drug Discov. 10, 439-452 (2011).
8. M. von Herrath, G. T. Nepom, Remodeling rodent models to mimic human type 1 diabetes. Eur. J. Immunol. 39, 2049-2054 (2009).
9. L. Chatenoud, J. Primo, J. F. Bach, CD3 antibody-induced dominant self tolerance in overtly diabetic NOD mice. J. Immunol. 158, 2947-2954 (1997).
10. L. Chatenoud, E. Thervet, J. Primo, J. F. Bach, Anti-CD3 antibody induces long-term remission of overt autoimmunity in nonobese diabetic mice. Proc. Natl. Acad. Sci. U.S.A. 91, 123-127 (1994).
11. L. Chatenoud, J. A. Bluestone, CD3-specific antibodies: A portal to the treatment of autoimmunity. Nat. Rev. Immunol. 7, 622-632 (2007).
12. K. C. Herold, S. Gitelman, C. Greenbaum, J. Puck, W. Hagopian, P. Gottlieb, P. Sayre, P. Bianchine, E. Wong, V. Seyfert-Margolis, K. Bourcier, J. A. Bluestone; Immune Tolerance Network ITN007AI Study Group, Treatment of patients with new onset type 1 diabetes with a single course of anti-CD3 mAb teplizumab preserves insulin production for up to 5 years. Clin. Immunol. 132, 166-173 (2009).
13. B. Keymeulen, E. Vandemeulebroucke, A. G. Ziegler, C.Mathieu, L. Kaufman, G. Hale, F. Gorus, M. Goldman, M. Walter, S. Candon, L. Schandene, L. Crenier, C. De Block, J. M. Seigneurin, P. De Pauw, D. Pierard, I. Weets, P. Rebello, P. Bird, E. Berrie, M. Frewin, H. Waldmann, J. F. Bach, D. Pipeleers, L. Chatenoud, Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. N. Engl. J. Med. 352, 2598-2608 (2005).
14. R. Hirsch, R. E. Gress, D. H. Pluznik, M. Eckhaus, J. A. Bluestone, Effects of in vivo administration of anti-CD3 monoclonal antibody on T cell function in mice. II. In vivo activation of T cells. J. Immunol. 142, 737-743 (1989).
15. K. C. Herold, S. E. Gitelman, U. Masharani, W. Hagopian, B. Bisikirska, D. Donaldson, K. Rother, B. Diamond, D. M. Harlan, J. A. Bluestone, A single course of anti-CD3 monoclonal antibody hOKT3γ1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes. Diabetes 54, 1763-1769 (2005).
16. K. C. Herold, W. Hagopian, J. A. Auger, E. Poumian-Ruiz, L. Taylor, D. Donaldson, S. E. Gitelman, D. M. Harlan, D. Xu, R. A. Zivin, J. A. Bluestone, Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N. Engl. J. Med. 346, 1692-1698 (2002).
17. N. Sherry, W. Hagopian, J. Ludvigsson, S. M. Jain, J. Wahlen, R. J. Ferry Jr., B. Bode, S. Aronoff, C. Holland, D. Carlin, K. L. King, R. L. Wilder, S. Pillemer, E. Bonvini, S. Johnson, K. E. Stein, S. Koenig, K. C. Herold, A. G. Daifotis; Protégé Trial Investigators, Teplizumab for treatment of type 1 diabetes (Protégé study): 1-year results from a randomised, placebo-controlled trial. Lancet 378, 487-497 (2011).
18. Tolerx, Tolerx and GSK Announce Phase 3 DEFEND-1 Study of Otelixizumab in Type 1 Diabetes Did Not Meet Its Primary Endpoint, http://www.tolerx.com/index. php?page=prdetail&id=204 [accessed 31 March 2011].
19. K. C. Herold, J. B. Burton, F. Francois, E. Poumian-Ruiz, M. Glandt, J. A. Bluestone, Activation of human T cells by FcR nonbinding anti-CD3 mAb, hOKT3γ1(Ala-Ala). J. Clin. Invest. 111, 409-418 (2003).
20. -/-, and C.B-17-scid/bg immuno-deficient mice. Hum. Immunol. 70, 790-802 (2009).
21. + human (h) cord blood (CB) cells. Clin. Immunol. 139, 321-335 (2011).
22. R. Ito, I. Katano, K. Kawai, H. Hirata, T. Ogura, T. Kamisako, T. Eto, M. Ito, Highly sensitive model for xenogenic GVHD using severe immunodeficient NOG mice. Transplantation 87, 1654-1658 (2009).
23. null mice are susceptible to lethal Salmonella Typhi infection. Proc. Natl. Acad. Sci. U.S.A. 107, 15589-15594 (2010).
24. J. Song, T. Willinger, A. Rongvaux, E. E. Eynon, S. Stevens, M. G. Manz, R. A. Flavell, J. E. Galán, A mouse model for the human pathogen Salmonella Typhi. Cell Host Microbe 8, 369-376 (2010).
25. T. Onoe, H. Kalscheuer, N. Danzl, M. Chittenden, G. Zhao, Y. G. Yang, M. Sykes, Human natural regulatory T cell development, suppressive function, and postthymic maturation in a humanized mouse model. J. Immunol. 187, 3895-3903 (2011).
26. + B cells. Immunology 134, 419-433 (2011).
27. C. Coisne, W. Mao, B. Engelhardt, Cutting edge: Natalizumab blocks adhesion but not initial contact of human T cells to the blood-brain barrier in vivo in an animal model of multiple sclerosis. J. Immunol. 182, 5909-5913 (2009).
28. J. S. Hyams, D. C. Wilson, A. Thomas, R. Heuschkel, S. Mitton, B. Mitchell, R. Daniels, M. A. Libonati, S. Zanker, S. Kugathasan; International Natalizumab CD305 Trial Group, Natalizumab therapy for moderate to severe Crohn disease in adolescents. J. Pediatr. Gastroenterol. Nutr. 44, 185-191 (2007).
29. 1 integrin, peripheral node addressin/l-selectin, and lymphocyte function-associated antigen-1 adhesion pathways. Am. J. Pathol. 159, 671-681 (2001).
30. C. Penaranda, Q. Tang, J. A. Bluestone, Anti-CD3 therapy promotes tolerance by selectively depleting pathogenic cells while preserving regulatory T cells. J. Immunol. 187, 2015-2022 (2011).
31. A. Kaser, O. Ludwiczek, S. Holzmann, A. R. Moschen, G. Weiss, B. Enrich, I. Graziadei, S. Dunzendorfer, C. J. Wiedermann, E. Mürzl, E. Grasl, Z. Jasarevic, N. Romani, F. A. Offner, H. Tilg, Increased expression of CCL20 in human inflammatory bowel disease. J. Clin. Immunol. 24, 74-85 (2004).
32. + gastric infiltrating lymphocytes in Helicobacter pylori gastritis. Infect. Immun. 75, 4357-4363 (2007).
33. S. M. Ivison, C. Wang, M. E. Himmel, J. Sheridan, J. Delano, M. L. Mayer, Y. Yao, A. Kifayet, T. S. Steiner, Oxidative stress enhances IL-8 and inhibits CCL20 production from intestinal epithelial cells in response to bacterial flagellin. Am. J. Physiol. Gastrointest. Liver Physiol. 299, G733-G741 (2010).
34. E. Esplugues, S. Huber, N. Gagliani, A. E. Hauser, T. Town, Y. Y. Wan, W. O'Connor Jr., A. Rongvaux, N. Van Rooijen, A. M. Haberman, Y. Iwakura, V. K. Kuchroo, J. K. Kolls, J. A. Bluestone, K. C. Herold, R. A. Flavell, Control of TH17 cells occurs in the small intestine. Nature 475, 514-518 (2011).
35. E. S.Woodle, D. Xu, R. A. Zivin, J. Auger, J. Charette, R. O'Laughlin, D. Peace, L. K. Jollife, T. Haverty, J. A. Bluestone, J. R. Thistlethwaite Jr., Phase I trial of a humanized, Fc receptor nonbinding OKT3 antibody, huOKT3γ1(Ala-Ala) in the treatment of acute renal allograft rejection. Transplantation 68, 608-616 (1999).
36. P. Simon, Q-Gene: Processing quantitative real-time RT-PCR data. Bioinformatics 19, 1439-1440 (2003).
37. E. Codorean, C. Nichita, L. Albulescu, E. Rǎ;ducan, I. D. Popescu, A. C. Lonitǎ;, R. Albulescu, Correlation of XMAP and ELISA cytokine profiles; development and validation for immunotoxicological studies in vitro. Roum. Arch. Microbiol. Immunol. 69, 13-19 (2010).
38. K. R. Garrod, M. D. Cahalan, Murine skin transplantation. J. Vis. Exp. 11, 634 (2008).